2022

INTS 2022

Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to the 15th International Neurotrauma Symposium meeting 2022 organized by the INTS, which will take place in Berlin, Germany, on July 17-20, 2022. A preclinical proof of concept study showing that Axoltis’ peptide NX210c, which is now at clinical stage of development, represents a new promising drug candidate for the treatment of Spinal Cord Injury, will be presented by the lab of Pr. Michael Fehlings (University Health Network, Toronto, Canada).

FENS 2022

Axoltis Pharma’s R&D Team, will attend FENS Forum 2022, the Europe’s largest international neuroscience conference, which will take place in Paris, France, on July 9-13th, 2022. Three posters will be presented, demonstrating the potential of our drug-candidate NX210cfor neurological pathologies.

 

Barriers of the CNS – Gordon Research Conference

Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to Gordon Research Seminar & Conference “Barriers of the CNS” which will take place in New London, NH, USA, on June 11-17, 2022. Dr. Lemarchant will present results showing that Axoltis’ peptide NX210c reinforces the integrity of blood-CNS barriers in vitro, which may represent an innovative therapeutic strategy to improve outcomes for patients with neurological pathologies. A study performed in collaboration with the lab of Pr. Matthew Campbell (Trinity College Dublin – Ireland).

Axoltis Pharma is delighted to be a contributor to this Gordon Research Conference !

https://www.grc.org/barriers-of-the-cns-conference/2022/

 

ENCALS 2022

Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to ENCALS meeting 2022, the Annual Meeting of the European Network to Cure ALS, which will take place in Edinburgh, Scotland, on June 1-3, 2022. Dr. Lemarchant will present a preclinical proof of concept study showing that Axoltis’ peptide NX210c, which is now at clinical stage of development, represents a new promising drug candidate for the treatment of Amyotrophic Lateral Sclerosis.

BRAIN & BRAIN PET

Dr. Mélissa Sourioux, Axoltis Pharma – Preclinical R&D Project Manager, will participate to Brain & Brain PET 2022, one of the top conferences in Neuroscience research which will take place in Glasgow, Scotland, on May 29th – June 1st. Dr. Sourioux will present results showing that Axoltis’ peptide NX210c improves synaptic recovery following ischemia in vitro and  demonstrate the rationale behind the use of NX210c in cognitive impairment due to long COVID.

BIO2022

 

Join Axoltis Pharma at BIO International Convention 2022 on June 13-16, with participation to the Bio One-on-One Partnering event.

Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our promising product.

AD/PD 2022

Drs. Sighild Lemarchant and Mélissa Sourioux, Axoltis Pharma – Preclinical R&D department, will participate to AD/PD™2022, which will take place online and onsite March 15-20, 2022. Our exciting results about the mechanism of action and the targets engaged by our product NX210c, ensuring synaptic transmission and BBB integrity reinforcement, will be presented. This confirms that our multi-properties product, which is now at clinical stage of development, has a large broad of applications in neurological pathologies.

2021

CTAD 2021

Dr Valérie Bourdès, Axoltis Pharma – Chief Medical Officer, will participate virtually to the Clinical Trials on Alzheimer’s Disease conference (CTAD) in Boston on November 9-12th, 2021. The results about our first-in-human clinical trial evaluating NX210 product in healthy volunteers will be presented. A good safety profile and initial promising pharmacodynamics effects are very encouraging for the future clinical development of the NX210 in patients with cognitive function impairment.

 

SFN 2021

Dr Sighild Lemarchant, Axoltis Pharma – PreClinical Project Manager, will participate to Neuroscience 2021, the Annual Meeting of Society for Neuroscience, which will take place online November 8-11, 2021. Dr Lemarchant will present our results about the mechanism of action and the targets engaged by our product NX210, leading to neuroprotection and synaptic transmission improvement. This confirms that our multi-properties product, which is now at clinical stage of development, has a large broad of applications in neurological pathologies.

 

ASIA 2021

Axoltis Pharma announces to attend the annual meeting of the American Spinal Injury Association (ASIA) on 8-10th July 2021 in Saint-Louis (USA). Dr Sighild Lemarchant, Preclinical Project Manager, will present the poster #99 entitled « SCO-spondin-derived peptide promotes functional recovery in a mouse model of spinal cord injury ». A study done in collaboration with the lab of Dr Cédric G. Geoffroy, Assistant Professor of Texas A&M University.

BNA 2021

Axoltis Pharma announces to attend the annual meeting of British Neuroscience Association,  International BNA2021 Festival of Neuroscience  (12-15 April 2021 Online and Worldwide). Axoltis Pharma preclinical research team is proud to present a poster (#TP001135) demonstrating a subcommissural organ-spondin-derived peptide restoring memory in a mouse model of Alzheimer’s disease.

 

AD/PD 2021

Axoltis Pharma announces to attend the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AP/PD 2021) (digital on March9-14th 2020). Axoltis Pharma preclinical reseach team is proud to present 3 posters (#P193, #P594, #P625) demonstrating the efficacy of its innovative drug candidate, a SCO-spondin derived peptide, in Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and excitotoxicity.

 

2020

Neuroscience Virtual Partnering – 2020


Axoltis Pharma will attend Neuroscience Virtual Partnering on November 9-12. Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our innovative drug-candidate for neurological disorders !

BIO Europe Digital 2020

Axoltis Pharma announces to attend BIO Europe 2020 Digital on October 26-29, with participation to the One-on-One Partnering event. This International Convention is one very important biotechnology event, drawing industry leaders. Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our promising lead product !

WFNR & SOFMER 2020

Axoltis Pharma announces to attend the 11th World Congress for NeuroRehabilitation (WFNR annual meeting) jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medecine annual (SOFMER annual meeting) (digital on October 7-11th 2020). Axoltis Pharma researcher team is proud to present 4 posters (#P0211, #P0212, #P0368, #P0651) demonstrating the efficacy of its innovative drug candidate, a SCO-spondin derived peptide, in cognitive impairement and traumatic spinal cord injury.

BIO 2020

Axoltis Pharma announces to attend BIO International Convention 2020 Digital on June 8-12, with participation to the Bio One-on-One Partnering event. The BIO International Convention is the world’s largest and most prestigious biotechnology event, drawing industry leaders from around the globe. Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our promising products.

BIO Europe Spring 2019 – Digital

Axoltis Pharma announces to attend BIO Europe Spring Convention 2020 Digital on March 23-25, with participation to the One-on-One Partnering event. This International Convention is one very important biotechnology event, drawing industry leaders from around the globe. Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our promising products.

2019

ISCoS 2019

Axoltis Pharma announces to attend the 58th International Spinal Cord Society (ISCoS) annual scientific meeting on November 5-7th at Nice, France. This is a great opportunity to meet with researchers from all over the world and arrange potential collaborative work.

NEUROSCIENCE 2019

Axoltis Pharma announces to attend NEUROSCIENCE 2019, the 50th Annual Meeting of the Society for Neuroscience, on October 19-23th at Chicago, Il, USA. NEUROSCIENCE is the world’s largest marketplace of ideas and tools for global neuroscience. This is a great opportunity to meet with researchers from all over the world and arrange potential collaborative work.

 

2019 PD Therapeutics Conference

Axoltis Pharma announces to attend MJFF 2019 Parkinson’s Disease Therapeutics Conference on October 15th at New York City, NY, USA. This meeting is The Michael J. Fox Foundation’s annual scientific conference and the only one in the world focused exclusively on Parkinson’s disease drug development. 

BioJapan 2019 & European Biotech Pharma Partnering Conference

Axoltis Pharma announces to attend BioJapan 2019. This Asia’s Premier Partnering Event for Biotechnology Industry will be held on October 9-11th at Pacifico Yokohama, Japan. On October 8th, Axoltis Pharma will also attend the European Biotech and Pharma Partnering Conference in Osaka, Japan. These are opportunities to meet us and discuss potential partnerships for the development of our promising products. Dr Yann GODFRIN, Chief Executive Officer, will be delighted to meet you there.

2019 International Congress of Parkinson’s Disease and Movement Disorders

Axoltis Pharma announces to attend the International Congress of Parkinson’s Disease and Movement Disorders Society (MDS), on September 22-26th at Nice, France. This is a great opportunity to meet with researchers and collaborators from all over the world and arrange potential collaborative work. Dr Manuel BLANC, Chief Scientific Officer, will be delighted to meet you there.